B-cell translocation gene 1 is downregulated by promoter methylation in ovarian carcinoma by 김현수





Journal of Cancer 
2017; 8(14): 2669-2675. doi: 10.7150/jca.21037 
Research Paper 
B-cell translocation gene 1 is downregulated by 
promoter methylation in ovarian carcinoma 
Ji-Ye Kim1,2*, Sung-Im Do3*, Go Eun Bae4,5 and Hyun-Soo Kim1 
1. Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea 
2. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea 
3. Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea 
4. Department of Pathology, The Catholic University of Korea Incheon St. Mary’s Hospital, Incheon, Republic of Korea 
5. Department of Pathology, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Republic of Korea 
*These authors have contributed equally to this work. 
 Corresponding author: Dr. Hyun-Soo Kim, Department of Pathology, Severance Hospital, Yonsei University College of Medicine, 50-1, Yonsei-ro, 
Seodaemun-gu, Seoul 03722, Republic of Korea. Tel: +82-2-2228-1794; Fax: +82-2-362-0860; Email: hyunsookim@yuhs.ac 
© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license 
(https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. 
Received: 2017.05.16; Accepted: 2017.06.27; Published: 2017.08.22 
Abstract 
A better understanding of tumor biology is important in the identification of molecules that are 
downregulated in malignancy and in determining their role in tumor suppression. B-cell 
translocation gene 1 (BTG1) has been shown to act as a tumor suppressor in several types of 
human malignancy. In this study, we analyzed BTG1 expression in ovarian carcinoma cell lines, and 
we investigated the mechanism underlying the observed alterations. The methylation status of the 
BTG1 promoter region was determined by methylation-specific polymerase chain reaction, and the 
effect of demethylation on BTG1 expression was analyzed. BTG1 protein expression in ovarian 
high-grade serous carcinoma tissue samples was evaluated using immunohistochemistry. BTG1 
mRNA and protein expression were reduced in ovarian carcinoma cells. In BTG1-silenced ovarian 
cancer cells, the BTG1 promoter was highly methylated. Treatment with 5-aza-deoxycytidine 
significantly elevated BTG1 mRNA and protein expression. Immunostaining demonstrated that 
BTG1 expression was significantly lower in ovarian carcinoma tissue samples than nonpathological 
ovaries and fallopian tubes. We demonstrated that BTG1 silencing in ovarian carcinoma occurs 
through epigenetic repression and is involved in the ovarian carcinogenesis. Our data suggest that 
BTG1 is a potential therapeutic target for patients with ovarian carcinoma. 
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Introduction 
Ovarian carcinomas account for more than 90% 
of ovarian malignancy and have the highest mortality 
rate of all gynecological tumors. Ovarian carcinomas 
are disproportionately deadly because of the lack of 
early detection methods; most ovarian carcinomas are 
diagnosed at advanced stages, resulting in a five-year 
survival rate of approximately 47% [1, 2]. Ovarian 
carcinomas are a heterogeneous group of tumors that 
exhibit a wide range of morphologies and clinical 
manifestations. An increased understanding 
regarding the alterations that occur in gene expression 
during ovarian carcinogenesis may result in the 
improvement of its diagnosis and treatment [3, 4]. 
Cellular proliferation, differentiation, and 
apoptosis are cell cycle-dependent processes [5]. 
Impaired cell cycle regulation is closely linked to 
tumor development and progression [6, 7]. Moreover, 
many proto-oncogenes and tumor suppressor genes 
are directly involved in or function as major factors in 
cell cycle regulation. Aberrant expression of these 
genes results in deregulation of the cell cycle, 
abnormal cellular proliferation, and tumor 
development [8]. While the existing treatment of 








aggressive surgery and chemotherapy, identification 
of novel biomarkers and gene targets may improve 
survival rate and quality of life of patients. Therefore, 
an understanding of the responsible genes in ovarian 
carcinogenesis and their molecular mechanisms is 
essential. 
 B-cell translocation gene 1 (BTG1) was originally 
identified as a translocation partner of the c-myc gene 
in B-cell chronic lymphocytic leukemia. BTG1 is a 
member of the mammalian BTG/Tob family that is a 
group of proteins with antiproliferative ability [9-11]. 
These proteins are involved in regulating cell cycle 
progression, inhibiting cellular proliferation, 
promoting apoptosis, and stimulating cellular 
differentiation in various cell types [12]. BTG1 is 
expressed predominantly in quiescent cells at the 
G0/G1 phase transition, with levels declining as cells 
enter S phase [13]. Exogenous expression of BTG1 was 
found to reduce proliferation, by G1 arrest and/or 
apoptosis, in murine fibroblasts [13]. Similarly, BTG1 
expression levels are inversely correlated with the 
proliferative capacity of murine microglial cells [14]. 
Moreover, enhanced BTG1 expression promotes 
differentiation of neural stem cells and germ cells, and 
plays an important role in angiogenesis. 
 Based on these characteristics, BTG1 is currently 
considered to be a tumor suppressor gene [15]. 
Experiments in gene expression induction showed 
that BTG1 mediated apoptosis and that it negatively 
regulated cellular proliferation, cell-to-cell adhesion, 
migration, and invasion in several human 
malignancies [16-22]. However, the role of BTG1 in 
the development and progression of ovarian 
carcinoma is yet to be elucidated. Moreover, the 
functions of BTG1 and its precise molecular 
mechanisms in ovarian carcinoma remain unclear. In 
this study, to clarify the roles of BTG1 in ovarian 
carcinogenesis, BTG1 mRNA and protein expression 
was evaluated in ovarian carcinoma cell lines; to 
understand the mechanism responsible for changes in 
BTG1 expression, we analyzed the promoter 
methylation status of BTG1 gene promoter region in 
ovarian carcinoma cell lines and compared BTG1 
expressions before and after demethylation treatment. 
Our results indicate that promoter hypermethylation 
is one of the mechanisms of BTG1 downregulation in 
ovarian carcinoma. 
Materials and Methods 
Cell lines and treatments 
The human ovarian carcinoma cell lines Caov-3, 
Caov-4, SW 626, OV90, and NIH:OVCAR3 were 
purchased from the American Type Culture 
Collection (Manassas, VA, USA) and maintained in 
Dulbecco’s Modified Eagle’s Medium or Roswell Park 
Memorial Institute (RPMI) 1640 medium 
supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), penicillin (100 U/mL), and streptomycin 
(100 μg/mL; Gibco, Life Technologies, Grand Island, 
NY, USA). All cell lines were cultured at 37°C in a 
humidified atmosphere of 5% CO2. 5-Aza-CdR 
(Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 
dimethyl sulfoxide (DMSO; Sigma-Aldrich) at 50 
mg/mL as a stock solution, which was stored at 
−20°C. DMSO concentration was 0.001%, and the 
same concentration was used as vehicle. Immediately 
before use, stock solutions were diluted in RPMI 1640 
without FBS. 
Quantitative reverse-transcriptase 
polymerase chain reaction (qRT-PCR) 
Total RNA was isolated using TRI Reagent 
(Molecular Research Center, Cincinnati, OH, USA) 
and used for cDNA synthesis with a ReverTra Ace 
qPCR RT Kit (Toyobo Co., Ltd., Osaka, Japan). The 
amount of cDNA was determined 
spectrophotometrically. The cDNA was used for 
qRT-PCR using the Bio-Rad CFX96 Real-Time PCR 
Detection System (Bio-Rad Laboratories, Hercules, 
CA, USA) with a C1000 Thermal Cycler (Bio-Rad 
Laboratories). PCR was carried out in a 20-μL reaction 
containing 0.5 μM of each primer, 10 μL of 2× 
SsoAdvanced SYBR Green Supermix (Bio-Rad 
Laboratories), and 2 μL of template DNA. PCRs for 
BTG1 and β-actin were initiated with a denaturing 
step at 95°C for 3 min, followed by 40 cycles at 95°C 
for 30 s and 60°C for 30 s. Amplification patterns were 
analyzed and threshold cycle numbers (Ct) for each 
sample were determined using CFX Manager 
Software (Bio-Rad Laboratories). The ΔΔCt method 
was used to calculate relative target gene expression 
after normalization to β-actin [23]. Amplification of 
the target gene was confirmed by melting curve 
analysis and target amplicon size was confirmed by 
agarose gel electrophoresis. Each sample was assayed 
in triplicate. 
Immunoblot analysis 
Cells were mixed with lysis buffer (50 mM Tris 
[pH 7.5], 1% NP-40, 10 mM NaCl, 20 μg/mL 
aprotinin, 20 μg/mL leupeptin, and 1 mM 
phenylmethylsulphonyl fluoride) and were placed on 
ice for 20 min. The lysates were assessed for protein 
concentration, and 100 μg of each protein sample was 
resolved by 12% SDS-PAGE and electroblotted onto 
nitrocellulose membranes (GE Healthcare, London, 
UK). After a 1-h incubation in blocking solution [5% 
non-fat milk in Tris-buffered saline with Tween 20 
(TBS-T)], the membranes were exposed to primary 




antibodies (anti-BTG1, 1:200, polyclonal; Abcam, 
Cambridge, MA, USA, and β-actin, 1:5,000; Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) overnight 
at 4°C. The blots were washed three times in TBS-T 
and incubated with horseradish peroxidase- 
conjugated secondary antibody (Cell Signaling 
Technology, Beverly, MA, USA) for 1 h at room 
temperature. Protein bands were visualized using 
enhanced chemiluminescence reagent (iNtRON 
Biotechnology, Seongnam, Gyeonggi-do, Republic of 
Korea). 
Methylation-specific PCR 
Genomic DNA was extracted using a 
NucleoSpin Tissue kit (Macherey-Nagel GmbH & Co. 
KG, Dueren, Germany) and treated with sodium 
bisulfite using an EZ DNA Methylation Kit (Zymo 
Research, Irvine, CA, USA). During the modification, 
unmethylated cytosines of the genomic DNA are 
converted to uracils, while methylated cytosines 
remained unchanged. The bisulfite-modified DNA 
subjected to PCR using primer pairs that specifically 
amplify either methylated or unmethylated sequences 
of BTG1. The following methylated BTG1-specific 
primers were used [24]: MSP1 (–149 to –289), 5′-GTT 
TTT AAG TTA AAA GGA AGG AAG TC-3′ (sense) 
and 5′-ATA TCA AAA AAT ATT AAA AAT CAC 
GCA-3′ (antisense); MSP2 (–517 to –645), 5′-TTT GAG 
GAG TTA GTT ATC GAG ATT C-3′ (sense) and 
5′-AAA TAA ATA AAA ACC GCC TAA CG-3′ 
(antisense). The following unmethylated 
BTG1-specific primers were used: USP1 (–149 to 
–289), 5′-GTT TTT AAG TTA AAA GGA AGG AAG 
TTG T-3′ (sense) and 5′-ATA TCA AAA ATA TTA 
AAA ATC ACA CA-3′ (antisense); USP2 (–517 to 
–645), 5′-TGA GGA GTT AGT TAT TGA GAT TTG 
G-3′ (sense) and 5′-AAA TAA ATA AAA ACC ACC 
TAA CAC A-3′ (antisense). MSP was performed in 
20-μL mixtures for 40 cycles using hot-start 
polymerase (Qiagen, Hilden, Germany). 
Tissue specimens 
 During the study period from January 2014 to 
December 2014, tissue samples were obtained from 37 
patients who underwent primary debulking surgery 
(hysterectomy, bilateral salpingo-oophorectomy, 
pelvic and/or paraaortic lymphadenectomy, 
omentectomy, and/or abdominopelvic 
peritonectomy) for primary ovarian high-grade 
serous carcinoma. The patients’ age ranged from 44 to 
76 years (median, 58 years). Two independent 
board-certified pathologists reviewed all hematoxylin 
and eosin-stained slides and selected the most 
representative slide from each case for 
immunohistochemical staining. Nine 
non-pathological ovaries and 14 non-pathological 
fallopian tubes were obtained from 23 patients who 
underwent hysterectomy with salpingo- 
|oophorectomy for uterine leiomyomata. This study 
(2016-07-007-001) was reviewed and approved by the 
Institutional Review Board at the Kyung Hee 
University Hospital at Gangdong (Seoul, Republic of 
Korea). 
Immunohistochemistry 
 Formalin-fixed tissues were dehydrated in a 
graded ethanol series and embedded in paraffin. 
Paraffin blocks were sectioned at 4 μm on a standard 
rotary microtome, and slices were brought from the 
water bath on clean slides. BTG1 protein expression 
was assessed by immunohistochemistry as described 
[25-30]. In brief, the 4-μm-thick, formalin-fixed, 
paraffin-embedded tissue sections were 
deparafﬁnized and rehydrated with a xylene and 
alcohol solution. Immunohistochemical staining was 
performed using a Ventana Benchmark XT automated 
staining system (Ventana Medical Systems, Tucson, 
AZ, USA) Antigen retrieval was carried out using Cell 
Conditioning Solution (CC1; Ventana Medical 
Systems). Sections were incubated with a rabbit 
polyclonal antibody against BTG1 (1:100; Abcam). 
After chromogenic visualization, using UltraView 
Universal DAB Detection Kits (Ventana Medical 
Systems), the slides were counterstained with 
hematoxylin. The slides were dehydrated following a 
standard procedure and sealed with coverslips. To 
minimize interassay variation, positive and negative 
control samples were included in each run. The 
positive control was normal liver and pancreatic 
tissue, and the negative control was prepared by 
substituting non-immune serum for the primary 
antibody; no staining was detected. 
Immunohistochemical evaluation 
 Immunohistochemical staining was analyzed by 
two independent board-certified pathologists. BTG1 
staining intensity was graded as absent (0), weak (1), 
intermediate (2), or strong (3). The staining proportion 
was graded as 0% (0), 1‒49% (1), 50‒74% (2), and 
75‒100% (3). The subcellular location of 
BTG1-positive signals (nuclear or cytoplasmic) was 
also estimated. The final score was calculated as the 
multiplication of staining intensity and proportion, 
resulting in scores of 0 (negative), 1‒2 (weakly 
positive), 3‒4 (moderately positive), 6‒9 (strongly 
positive) [24, 25, 27, 28, 31]. Disagreements between 
the two pathologists were resolved by consensus. 
Statistical analysis 
 We used the Wilcoxon test to compare 
expression levels of BTG1 mRNA before and after 




5-aza-CdR treatment in each ovarian carcinoma cell 
line examined. Chi-square or Fisher’s exact test were 
used to compare BTG1 immunoreactivity between 
ovarian carcinoma and normal tubo-ovarian tissue 
samples. Statistical analyses were performed using 
PASW Statistics for Windows (version 18.0; Armonk, 
NY, USA). Statistical significance was defined as a P 
value less than 0.05. 
Results 
BTG1 expression in ovarian carcinoma cell 
lines 
 BTG1 protein was expressed at different levels 
in different ovarian carcinoma cell lines. The Caov-3, 
Caov-4, SW 626, and OV90 lines exhibited reduced 
BTG1 protein expression (Figure 1A). Consistent with 
these findings, Caov-3 (normalized expression ratio, 
0.20), Caov-4 (normalized expression ratio, 0.30), and 
SW 626 (normalized expression ratio, 0.60) cell lines 
showed significantly lower BTG1 mRNA expression 
than the OV90 (normalized expression ratio, 4.10) and 
NIH:OVCAR3 (normalized expression ratio, 1.30) cell 
lines (Figure 1B). BTG1 mRNA was readily detected 
in the OV90 line, while it was negligible in Caov-3 and 
Caov-4. 
Mechanism contributing to reduced BTG1 
expression in ovarian carcinoma cell lines 
Zheng and colleagues [24] found that BTG1 
mRNA and protein expression are reduced in gastric 
carcinoma cell lines. The authors also showed that 
BTG1 promoter methylation was decreased, and 
mRNA expression restored after treatment with the 
demethylating agent 5-aza-deoxycytidine 
(5-aza-CdR), indicating that BTG1 downregulation is 
associated with BTG1 promoter hypermethylation. 
Based on their observations, we hypothesized that 
promoter hypermethylation might explain the 
reduced BTG1 expression observed in ovarian 
carcinoma cell lines. We detected BTG1 promoter 
hypermethylation in all of Caov-3, Caov-4, SW 626, 
OV90, and NIH:OVCAR3 cell lines using 
methylation-specific polymerase chain reaction 
(MSP), indicating that promoter methylation may be a 
possible mechanism for the reduced BTG1 expression 
in these cell lines (Figure 1C). 
 To investigate the effect of methylation on BTG1 
downregulation, we treated the cell lines with 
5-aza-CdR. 5-Aza-CdR treatment significantly 
reduced BTG1 promoter methylation in Caov-3, 
Caov-4, and SW 626 (Figure 2A). This reduction was 
associated with significant restoration of BTG1 mRNA 
expression, with a 4.0-fold increase in Caov-3 (P < 
0.001), a 1.37-fold increase in Caov-4 (P < 0.001), and 
1.59-fold increase in SW 626 (P < 0.001), as compared 
to the respective pretreatment levels (Figure 2B). The 
restorative effect of 5-aza-CdR on BTG1 expression in 
these cell lines was confirmed by Western blotting 
(Figure 2C). These findings indicate that promoter 
methylation is directly responsible for the reduced 
BTG1 expression in ovarian carcinoma cell lines. 
 
 
Figure 1. BTG1 expression is downregulated by promoter methylation in 
ovarian carcinoma cell lines. (A) Western blot for BTG1. (B) Normalized BTG1 
mRNA expression analyzed by qRT-PCR. (C) Methylation status of the BTG1 
gene promoter region analyzed by MSP. 
 
BTG1 expression in ovarian carcinoma tumor 
tissues 
Using immunohistochemistry, we investigated 
BTG1 protein expression in tissue samples of ovarian 
carcinoma, non-pathological ovaries, and 
non-pathological fallopian tubes. BTG1 
immunoreactivity was predominantly cytoplasmic, 
although weak-to-moderate nuclear staining was 
observed. Normal pancreas (Figure 3A) and liver 
(Figure 3B) tissue sections were used as positive 
controls and exhibited diffuse and moderate-to-strong 
BTG1 immunoreactivity. BTG1 was not detected in 
the extracellular matrix or connective tissues. Eight 
out of nine (88.9%) non-pathological ovaries and 12 
out of 14 (85.8%) non-pathological fallopian tubes 




(Figure 3C) exhibited diffuse and strong BTG1 
immunoreactivity (Figure 3D). The remaining one 
(11.1%) non-pathological ovary and two (14.3%) 
non-pathological fallopian tubes showed moderately 
positive BTG1 expression. BTG1 protein was localized 
within the ovarian stromal cells and tubal epithelium. 
In contrast, in the carcinoma tissue samples (Figure 
3E) BTG1 expression was strongly to moderately 
positive in 27.0% (10/37; Figure 3F), weakly positive 
in 37.8% (14/37; Figure 3G), and negative in 35.1% 
(13/37; Figure 3H). BTG1 protein expression in 
ovarian carcinoma was significantly lower than in 
non-pathological ovarian and tubal tissue samples (P 
< 0.001; Table 1). 
 
 
Table 1. Differences in BTG1 expression between ovarian 
carcinoma and non-pathological ovary and fallopian tube 








ovary and fallopian 
tube 
23 0 (0.0) 0 (0.0) 3 (13.0) 20 (87.0) <0.001* 





Figure 2. Effect of treatment with 5-aza-CdR on promoter methylation status 
and BTG1 expression in ovarian cancer cell lines. (A) Reduction in methylation 
of the BTG1 gene promoter region by treatment with 5-aza-CdR. (B) 
Restoration of BTG1 mRNA expression by treatment with 5-aza-CdR. ***P < 
0.001 versus pretreatment. (C) Western blot for BTG1 before and after 
demethylation. 
Discussion 
In this study, we analyzed the expression of 
BTG1 in human ovarian carcinoma cells and tissues. 
We observed that ovarian carcinoma cell lines 
exhibited reduced BTG1 mRNA and protein 
expression, and that 73.0% (27/37) of ovarian 
carcinoma tissue samples had significantly reduced 
BTG1 protein expression. These findings indicate that 
BTG1 expression is downregulated in ovarian 
carcinoma, suggesting BTG1 as a potential diagnostic 
biomarker for ovarian carcinoma. 
 We investigated the regulatory mechanisms for 
BTG1 gene expression. One possible mechanism that 
could explain BTG1 downregulation was gene 
promoter methylation. Treatment with the 
demethylating agent 5-aza-CdR significantly restored 
BTG1 mRNA expression in the ovarian carcinoma cell 
lines Caov-3, Caov-4, and SW 626, which had very 
low basal mRNA levels. Consistent herewith, 
5-aza-CdR treatment increased BTG1 protein 
expression in these cell lines. These findings suggest 
that epigenetic mechanisms are responsible for 
repressed BTG1 expression in ovarian carcinoma cells. 
We confirmed DNA methylation status of the BTG1 
gene promoter region using MSP. Downregulation of 
BTG1 expression in the ovarian carcinoma cell lines 
was a result of enhanced promoter methylation, 
indicating that aberrant promoter hypermethylation 
was indeed the cause of BTG1 silencing in ovarian 
carcinoma cell lines. Similar to our findings, Zheng et 
al. [24] observed reduced BTG1 expression in gastric 
carcinoma, where they found that BTG1 mRNA and 
protein expression were significantly reduced in 
gastric carcinoma cell lines examined, and that BTG1 
was silenced due to promoter hypermethylation. 
They also showed that after treatment with 
5-Aza-CdR, BTG1 promoter methylation was 
suppressed and mRNA expression restored in these 
cell lines. Taken together, these results provide a new 
insight into the alterations of BTG1 expression 
associated with ovarian carcinoma development. We 
suggest that therapeutic targeting of BTG1 is a 
potential strategy for the treatment of ovarian 
carcinoma. 
 However, experimental data on BTG1 promoter 
methylation in other types of human malignancy are 
in conflict with the above findings. Kanda et al. [32] 
reported that gastric cancer and hepatocellular 
carcinoma cell lines do not exhibit BTG1 promoter 
hypermethylation. These conflicting findings 
regarding promoter methylation status may be owing 
to the differences in organs and cell types, differences 
in methods for analyzing methylation status, and the 
inadequacy of a single model for explaining 
carcinogenesis. Furthermore, downregulation of 




BTG1 expression has also been linked to alternative 
molecular regulatory mechanisms, such as 
microRNAs, in renal cell carcinoma and prostate 
carcinoma [33, 34]. Taken together, these findings 
indicate that promoter hypermethylation may be 
partially responsible for repressed BTG1 expression. 
Data on BTG1 expression in other types of 
human malignancy support the notion that BTG1 may 
function as a tumor suppressor. Sun et al. [20] showed 
that BTG1 protein expression was significantly lower 
in renal cell carcinoma tissues than in normal kidney 
tissue. They also observed that BTG1-overexpressing 
renal cell carcinoma cells, obtained by stable 
transfection of BTG1 cDNA, had significantly lower 
viability, higher apoptotic rate, and lower invasion 
capability than control cells, accompanied by 
decreased expression of cyclin D1, B-cell lymphoma 2, 
and matrix metalloproteinase 9. These findings 
indicated that BTG1 can regulate cell cycle, inhibit 
cellular proliferation by reducing B-cell lymphoma 2, 
and modulate invasion and metastasis by 
downregulating matrix metalloproteinase expression. 
Similarly, BTG1-transfected hepatocellular carcinoma 
cells [18], non-small cell lung carcinoma cells [19], and 
nasopharyngeal carcinoma cells [17] correlated with 
lower survival, more frequent G0/G1 arrest, higher 
apoptotic rate, and significantly lower invasiveness 
than corresponding untransfected cells. Zhu et al. [22] 
demonstrated that BTG1-transfected breast carcinoma 
cell xenografts had significantly smaller tumor size, 
lower cell density, and a higher degree of tumor 
necrosis than untransfected xenografts in control 
mice, indicating that BTG1 overexpression mediates 
inhibition of xenograft formation and breast 
carcinoma cell growth in vivo. 
Reduced BTG1 expression seems to point toward 
aggressive oncogenic behavior. Reduced BTG1 
expression is significantly associated with lymph 
node metastasis, higher histological grade, advanced 
clinical stage, as well as reduced overall survival in 
carcinomas of the thyroid [8], 
esophagus [16], nasopharynx [17], 
lung [19], liver [35], and breast [36]. 
Zheng et al. [24] reported that reduced 
BTG1 expression was associated with 
deeper invasion, lymphovascular 
invasion, lymph node metastasis, and 
advanced stage of gastric carcinoma, 
indicating that BTG1 expression is a 
biomarker for predicting the 
aggressiveness of this carcinoma. 
Zhao et al. [4] observed that BTG1 
mRNA expression in International 
Federation of Gynecology and 
Obstetrics (FIGO) stage I–II ovarian 
carcinomas was higher than that in 
FIGO stage III–IV ovarian carcinomas. 
These data suggest that BTG1 
downregulation may be a major 
contributor to tumor development 
and progression, and that BTG1 
expression scores may provide 
valuable information for the 
assessment of treatment options, 
prognosis judgment, and prediction of 
disease severity. 
Conclusion 
 We observed that BTG1 was 
downregulated in ovarian carcinoma 
cell lines and tissues, suggesting that 
this protein is involved in the 
regulation of ovarian carcinoma 
development and downregulated 
BTG1 expression may promote 
 
 
Figure 3. BTG1 protein expression in non-pathological fallopian tube and ovarian carcinoma tissue 
samples. As a positive control, (A) normal pancreas and (B) normal liver display strong BTG1 
immunoreactivity. (C) Non-pathological fallopian tube consists of a single layer of mucosal epithelium 
with multiple plicae. (D) Non-pathological tubal epithelium exhibits strong BTG1 immunoreactivity. (E) 
Histopathology of tubo-ovarian high-grade serous carcinoma. (F) Strongly positive, (G) weakly positive, 
and (H) negative BTG1 expression in ovarian carcinoma tissue samples. 
 




malignant transformation. We demonstrated that 
BTG1 expression was restored after demethylation 
treatment in ovarian carcinoma cells, suggesting that 
downregulation of BTG1 by promoter 
hypermethylation may be one mechanism 
contributing to the ovarian carcinogenesis. These 
results corroborate that BTG1 expression may be a 
tumor suppressor. Restoration of BTG1 expression 
may offer a new therapeutic approach for treating 
patients with ovarian carcinoma. 
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